SciSparc

SciSparc Ltd. is a professional clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, led by a team of experienced senior executives and scientists. The company is committed to creating and enhancing a portfolio of technologies and assets based on cannabinoid drugs. Based on this, the company is currently advancing the following drug development programs, which involve the repurposing of the FDA-approved cannabinoid Dronabinol: THX-110 for the treatment of Tourette Syndrome (TS), obstructive sleep apnea (OSA), and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. On January 18, 2021, Therapix Biosciences Ltd. officially announced the change of its company name to SciSparc Ltd.